Extended IASD Investigation: REDUCE LAP-HF IV
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04632160|
Recruitment Status : Not yet recruiting
First Posted : November 17, 2020
Last Update Posted : November 17, 2020
Multicenter, Prospective, Open Label, Single Arm, Clinical Trial.
The primary objective of this clinical trial is to further evaluate the safety and clinical efficacy of the IASD System II in symptomatic heart failure patients with an left ventricular ejection fraction (LVEF) ≥ 40%, and elevated left sided filling pressures despite standard Guideline Directed Medical Therapy (GDMT); and to compare the safety and efficacy results to those from the treatment arm of the REDUCE LAP-HF Randomized Trial II (Corvia protocol 1601).
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure With Preserved Ejection Fraction Heart Failure With Mid Range Ejection Fraction||Device: IASD System II||Not Applicable|
Participants are screened against non-invasive eligibility criteria and scheduled for a hemodynamic evaluation. Following right heart catheterization at rest and during supine bicycle exercise, patients will undergo a brief intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE) exam for septal suitability.
Eligible patients continue with, fluoroscopically and echo guided transseptal puncture and IASD System II implant procedure. If a previously unknown protocol exclusion is discovered during the index procedure, and device is not implanted, participant is followed for 30 days, and then exits the study.
Participants return for follow-up exams 30 days after the implant procedure and annually for 5 years after the implant procedure. In-person visits will take place for the first 2 years. Telephone follow-up and medical chart review will be conducted for years 3-5.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Study to Evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure|
|Estimated Study Start Date :||January 1, 2021|
|Estimated Primary Completion Date :||January 1, 2022|
|Estimated Study Completion Date :||January 1, 2027|
Treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
Device: IASD System II
The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
Other Name: Interatrial Shunt Device
- Incidence of and time-to-cardiovascular mortality or first non-fatal, ischemic stroke through 12 months [ Time Frame: 12 Month ]
- Total rate (first plus recurrent) per patient year of heart failure (HF) admissions or healthcare facility visits for IV diuresis for HF up to 24 months, analyzed when the last subject completes 12 month follow-up, and time-to-first HF event [ Time Frame: Up to 24 Months ]
- Change in baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) total summary score at 12 months [ Time Frame: 12 Month ]
- Cardiovascular mortality through 12 months [ Time Frame: 12 Months ]
- Non-fatal, ischemic stroke through 12 months [ Time Frame: 12 Months ]
- New onset or worsening of kidney dysfunction (defined as eGFR decrease of > 20 ml/min/1.73 m2) through 12 months [ Time Frame: 12 Months ]
- Incidence of Major Cardiac Events i. Cardiac death ii. Myocardial infarction iii. Cardiac tamponade iv. Emergency cardiac surgery. [ Time Frame: 12 Months ]
- Thrombo-embolic complications (TIA, systemic embolization) through 12 months [ Time Frame: 12 Months ]
- ≥30% increase in right ventricular size/decrease in TAPSE through 12 months [ Time Frame: 12 Months ]
- Newly acquired persistent or permanent AF or atrial flutter through 12 months [ Time Frame: 12 Months ]
- Total rate per patient year of heart failure admissions or healthcare facility visits for IV diuresis or visits with intensification of oral diuresis for HF through 24 months, analyzed when the last subject completes 12 months follow-up [ Time Frame: Up to 24 months ]
- Change in New York Heart Association (NYHA) functional Class between baseline and 12 months [ Time Frame: 12 Months ]
- Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score between baseline and 12 months, categorized as ≤0, >0 - 5, >5 - 10, >10 - 15, >15 - 20, >20 - 25, >25. [ Time Frame: 12 Months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04632160
|Contact: Jan Komtebedde, DVMemail@example.com|
|Contact: Katie Romcevich, BSBAfirstname.lastname@example.org|
|Principal Investigator:||Sanijv Shah, MD||Northwestern Memorial Hospital|
|Principal Investigator:||Marty Leon, MD||Columbia University Irving Medical Center|